I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
Another biopharma executive went before Congress to explain drug price hikes. Unlike Martin Shkreli, Mylan CEO Heather Bresch actually answered questions. Taking heat over the EpiPen scandal, she tried to stick... Read more »
Nearly ten years ago, academics at Stanford University trying to divine how proteins fold into their complicated shapes—an action that can take a millionth to a thousandth of a second—began recruiting... Read more »
[Updated, 9/12/16, 2:35 p.m. See below.] French healthcare giant Sanofi (NYSE: SNY) and Verily, the life-science group within Google’s parent company Alphabet (NASDAQ: GOOG), are each putting... Read more »
[Corrected, 9/12/16, 4:28 p.m. See below.] What do cancer experts want? The moon, perhaps. As part of the Obama administration’s “cancer moonshot” program, a panel of scientists this week... Read more »
The Obama administration wants to speed up cancer research with its “Cancer Moonshot” program—packing 10 years’ worth of work on prevention and treatment programs into five is one of its rallying... Read more »
Moderna Therapeutics, whose unusual and still unproven drug-producing technology has attracted more than a billion dollars in funding and partnerships, is joining the scramble to produce a vaccine to protect against... Read more »
Thanks to remarkable results in a small group of patients, including former U.S. President Jimmy Carter, cancer immunotherapy has spurred talk of once impossible-to-imagine cures and has gained its share,... Read more »
A man who helped shed light—fluorescent light—on biology died far too early, at the age of 64. Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon... Read more »
Neuroscience startup Denali Therapeutics said Thursday it has added $130 million in privately-raised cash, in part to push a drug program into clinical trials in Europe.
The South San Francisco, CA-based... Read more »
[Updated 8/24/16, 1 a.m. See below.] A new program to prepare high-ranking women in the biotech industry for corporate board seats has unveiled its first class of 20.
In... Read more »
When the Olympics roll around, many watchers get into a sport they previously hadn’t thought much about. This time for me, it’s volleyball.
The men’s and women’s games, both indoor and... Read more »
The authors of a study published Tuesday in the Journal of the American Medical Association argue that the new wave of cholesterol-fighting drugs, hailed as a big medical step forward when... Read more »
The U.S. government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including... Read more »
Three years ago, international drug firm GlaxoSmithKline (NYSE: GSK) unveiled a new effort to create tiny implantable devices that would use electricity, not drugs, to alter the course of a... Read more »
Quarterly biopharma earnings added a little heat to the already high summer temperatures. Amongst several companies to report this week, the biggest news came from Gilead Sciences (NASDAQ: GILD), whose... Read more »
The big drug news from the annual Alzheimer’s Association meeting this week involved companies that have found silver linings in otherwise gloomy data—a recurrent theme in Alzheimer’s clinical work. The trials... Read more »
Kadmon Holdings tempered its expectations and managed to go public late Wednesday, despite its founders’ criminal history and a heavy debt load.
New York-based Kadmon raised $75 million by selling 6.25... Read more »
A foundation affiliated with Purdue University in West Lafayette, IN, is raising $10 million for a new venture fund that would help the school’s spinouts. That doesn’t seem like much, but... Read more »
October 27, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.